JAMA Neurol:Lanabecestat治疗早期AD研究失败

2019-11-27 MedSci MedSci原创

lanabecestat无法减缓早期AD患者认知或功能下降

近日研究人员考察了人β-淀粉样蛋白前体裂解酶1(BACE1/β-分泌酶)抑制剂Lanabecestat对AD的治疗效果。

AMARANTH和DAYBREAK-ALZ研究均为随机、安慰剂对照、第2/3期和3期临床试验,持续时间分别为104周和78周。年龄在55岁至85岁之间的符合美国老年痴呆症协会早期或轻度AD标准的患者参与研究,接受认知筛查并证实淀粉样蛋白的存在。研究的主要结局指标是13项阿尔茨海默病评估量表(认知亚量表)较基线的变化。次要结果包括阿尔茨海默病合作研究-日常生活工具活动量表、临床痴呆评估、功能活动问卷、微型精神状态检查。

AMARANTH研究包含2218例患者,平均年龄71.3岁,女性1177例(53.1%)。DAYBREAK-ALZ研究包含1722例患者中,平均年龄72.3岁,女性1023例(59.4%)。两项研究均在无效分析后提前终止。组间主要或次要疗效指标差异不显著。与安慰剂组相比,服用lanabecestat组的患者中,精神不良事件、体重减轻和发色改变的比例更高。

研究认为,lanabecestat无法减缓早期AD患者认知或功能下降。

原始出处:



本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051472, encodeId=19bb20514e2a7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 14 23:28:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000925, encodeId=c2a920009256f, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 08 22:28:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633542, encodeId=b191163354206, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 08 15:28:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035815, encodeId=19ba1035815ab, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Nov 27 21:28:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051472, encodeId=19bb20514e2a7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 14 23:28:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000925, encodeId=c2a920009256f, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 08 22:28:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633542, encodeId=b191163354206, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 08 15:28:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035815, encodeId=19ba1035815ab, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Nov 27 21:28:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2020-06-08 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051472, encodeId=19bb20514e2a7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 14 23:28:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000925, encodeId=c2a920009256f, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 08 22:28:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633542, encodeId=b191163354206, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 08 15:28:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035815, encodeId=19ba1035815ab, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Nov 27 21:28:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2020-01-08 AspirantSuo
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051472, encodeId=19bb20514e2a7, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Apr 14 23:28:00 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2000925, encodeId=c2a920009256f, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Jun 08 22:28:00 CST 2020, time=2020-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633542, encodeId=b191163354206, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Wed Jan 08 15:28:00 CST 2020, time=2020-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035815, encodeId=19ba1035815ab, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Nov 27 21:28:00 CST 2019, time=2019-11-27, status=1, ipAttribution=)]
    2019-11-27 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Lancet Neurol:成年后血压与老年脑结构变化

从成年早期到中年,高血压和血压的增加与老年WMHV的增加和脑体积的缩小有关

Sci transl med:GHSR1拮抗剂联合DRD1拮抗剂可改善AD病变

海马区对于记忆的形成和认知至关重要。海马区病变是阿尔兹海默症(AD)最早发生的病理变化;但其潜在分子机制尚不明确。既往研究通过对AD患者和小鼠模型的脑组织样本进行尸检发现海马区病理性β淀粉样蛋白直接与“饥饿激素”胃饥饿素(GHSR1α)受体结合并抑制其功能。在小鼠模型中,结合封闭GHSR1α介导的多巴胺受体D1(DRD1)激活,导致突触可塑性损伤和记忆丧失。目前对AD的治疗在纠正海马区突触缺陷方面

Lancet Neurol:降压药与高血压人群痴呆风险

长期的观察发现,抗高血压药物可降低高血压人群痴呆风险,但对于血压正常人群则无显著效果

Sci transl med:MS4A基因调控TREM2的表达,影响AD发病风险

既往研究表明,脑脊液(CSF)可溶性髓样细胞触发受体2(sTREM2)与阿尔兹海默症(AD)相关;TREM2突变与AD风险有关,在AD进展过程中,CSF中的sTREM2的浓度不断变化。TREM2在小胶质细胞的活化、存活和吞噬过程中起着关键作用;但,sTREM2在AD中的病理生理作用尚不明确。研究人员进行了一项全基因组关联研究(GWAS),以鉴定来源于阿尔茨海默病神经成像计划的CSF sTREM2的

JAMA Neurol:二甲胺四环素治疗轻度AD效果不显著

二甲胺四环素不能延缓轻度阿尔兹海默患者认知及功能衰退

JAMA Neurol:微管稳定剂TPI-287在一系列tau蛋白相关神经退行性疾病中的应用

研究认为,微管稳定剂TPI-287对多种Tau蛋白相关疾病具有潜在的治疗效果,同时确定篮子设计在神经退行性疾病的早期开发中的价值。